Summary We wished to develop and validate a simple linear analogue self-assessment (LASA) scale to assess utility values in multicentre, multicultural breast cancer trials. We compared two variants of a LASA scale (score range 0-100) with different anchoring points [perfect health to worst possible health (subjective health estimation, SHE) and perfect health to death (SHED)] in 84 patients with advanced breast cancer. Feasibility was explored in the first 48 patients interviewed. Values from the LASA scales were compared with each other and with a time trade off (TTO) interview. Scores from the two LASA scales were highly correlated (r = 0.8, P < 0.0001, Spearman). The relationship between TTO interview and SHE was confirmed with tests for trend across ordered groups (linear-trend test P < 0.001). Most patients preferred SHE to SHED. SHE scores (in which high scores indicate high-health-state values) were significantly different by type of treatment, time from diagnosis and age. Thus, significantly different mean SHE scores were obtained from patients receiving no treatment or hormone therapy, mild and intensive chemotherapy (ANOVA P = 0.03) and from patients with diagnosis 2 years, 2-5 years, 5-10 years and more than 10 years before interview (ANOVA P = 0.02). Older patients (> 56 years) had a lower mean on the SHE scale (53 vs 61; ANOVA P = 0.04). We found that the two versions of the LASA scale were equivalent for clinical purposes. SHE appeared to provide a feasible, patient-preferred and valid alternative to lengthy TTO interviews in assessing the value patients attach to their present state of health in large-scale cancer clinical trials.
Clinical trials increasingly measure patients' subjective experience as well as duration of life. Two different approaches to quantitative assessment of patients' subjective experience have emerged: health-related quality of life (HRQL) and utility. The concept of quality of life has its roots in psychosocial science and includes physical, emotional, social and sometimes also cultural and spiritual components of subjective experience. Multidimensional scales have been developed to allow patient self-assessment of HRQL.
The concept of utility is derived from economical science. Utilities may be defined as patient-stated preferences for various health states under conditions of uncertainty. Utility values, when based on both subjective experience and HRQL, may change over time. In medical applications, a utility value is associated with a certain health state. It is usually denoted by a value between 0 (equivalent to death) and 1 (perfect health). Various methods have been used to measure utilities (Torrance, 1976 (Torrance, , 1987 Feeny et al, 1989; Kaplan et al, 1990) . In the 'standard gamble' method, an interviewer asks subjects to make a choice between various probabilities of survival for different options. In the 'time trade-off' (TTO) approach, subjects assess equivalence between a shorter length of life in perfect health and a longer period in the particular health state. Utility values are more easily integrated than are HRQL scores with the conventional end points to allow weighted comparison of times spent in different health states. Their disadvantage, particularly in large clinical trials, is the amount of time and resources required (Weeks, 1991; Guyatt et al, 1993) . Previous attempts to use simple rating scales as measures of utility (Ross et al, 1978; Sutherland et al, 1983; Read et al, 1984; Torrance, 1986; Noack, 1990) have shown varying degrees of agreement with the standard gamble and ITO methods.
The Q-TWiST model developed by Goldhirsch (1986, 1989 ) is a utility-based assessment that divides the life-span of the patients from the beginning of adjuvant treatment until death into three time segments corresponding to distinct health states: TOX (time with toxicity from treatment), TWiST (time without symptoms of treatment or disease) and REL (time from relapse until death). TOX and REL are weighted by arbitrary utility coefficients and added to TWiST to reach an overall assessment of different treatment groups. The shortcoming of the Q-TWiST method thus far is that utility coefficients for the different health states have been assigned arbitrarily.
The International Breast Cancer Study Group (IBCSG) is a large co-operative group that conducts clinical trials of adjuvant treatments in patients with early breast cancer. Since 1985, we have developed methods to assess HRQL and to integrate utilities with the conventional end points of disease-free and overall 985 survival in IBCSG trials (i.e. Q-TWiST). To estimate HRQL, we adapted the patient-rated Linear Analogue Self Assessment (LASA) scales, assessing four broad components of HRQL: physical well-being, appetite, emotional well-being and coping. HRQL data from the first two large trials yielded clinically meaningful results (Hurny et al, 1996) .
Although arbitrary utility coefficients in the Q-TWiST model can provide a useful decision aid for threshold analysis (Cole et al, 1995; Gelber et al, 1996) , we wished to assess patients' own utilities directly in a manner suitable for large international trials. As the HRQL assessments in our trials use a LASA format, we designed two LASA scales for health state estimation. As a first step we compared the two scales, then we validated the preferred scale by direct comparison with time trade-off questions.
PATIENTS, METHODS AND PROCEDURES Patients and procedures
We studied ambulatory patients with metastatic or inflammatory breast cancer seen for treatment or routine check-ups at university or cantonal hospitals in three language areas of Switzerland. Eligible patients were aged 20-75 years, had experienced chemotherapy, had an ECOG performance status of 0-3, were free of psychiatric illness, were able to respond to interview questions in one of the three study languages and gave informed consent. Ethical committee approval was obtained for each participating institution.
Medical data were abstracted from the medical records after obtaining informed consent from the patient, but before interview. At the time of the interview, sociodemographic data were collected from patients. Patients first completed the LASA questionnaire, then the TTO interview.
Two LASA scales were prepared as utility measures. First, in order to cover the entire range of theoretical utilities, the SHED scale used 'perfect health' and 'death' as descriptions of the ends of the scale. Because of concern that use of the word 'death' might cause distress, a second LASA scale (the SHE scale) used (perfect health' and 'worst possible health' (for full wording see Appendix 1). The time frame specified 'the rest of your life'. Translations into the three required languages followed the procedures of forward and backward translation suggested by the EORTC quality of life working group (unpublished manuscript by EORTC translation work group, 1992), using professional translators. The final translations were checked for linguistic equivalence by clinicians involved in the study who were fluent in the languages concerned and familiar with the concepts of health-state assessment. The questionnaire form contained the SHED and SHE scales, together with four LASA scales for the HRQL indicators physical well-being, mood, appetite and coping (Hurny et al, 1992 (Hurny et al, , 1993 .
In the time trade-off questions (TTO), patients were asked to trade between 12 months in their current state of health and an equal or smaller amount of time (12, 11, 9, 6, 3 , 1 or 0 months) in perfect health (Weeks, 1991) . (The full text of the TTO questions is given in Appendix 2.) As our patients were severely ill, 'the rest of your life' was about 1 year, which corresponded to the timeframe in the TTO question. According to our hypothesis, there should have been a close correspondence between the worth attached to the current health state in the 1T0 and the rating scale.
After completion of the TTO questions, the patients from the two German-speaking centres were asked about their reaction to the investigation. Nine questions were asked on patients' general reaction to the previous questioning, emotional and other difficulties in answering the TTO questions and thoughts going through their minds when placing a mark on the SHE and SHED scales. Patients' answers to these nine questions were categorized by two of the authors (BvW, MB) by a consensus rating. Patients from the other language areas were not formally assessed concerning their reaction to the investigation but were encouraged to give their opinion about the interview and the topic of investigation at the end of the TTO questions. Interviews were conducted by physicians, by a psychologist and by research nurses. All interviewers were provided with a written protocol on the study purpose and data collection procedures (including visual aids) to standardize the assessments in the different centres and were personally instructed and trained in TTO interviewing by one of the authors (BvW or JB).
In summary, the study was performed in two steps: first, in centres in the German-speaking area, TTO interviews were performed; SHED, SHE and HRQL scales were filled out; and the reaction to the investigation was assessed. Then, the investigation was expanded to centres in the French-and Italian-speaking areas, including TTO interview, SHE and HRQL assessment only.
Statistical analysis
In order to determine whether the two scales could be used interchangeably, at least so that SHE could replace SHED with sufficient accuracy for the intended purpose of measurement, SHED and SHE were checked for 'comparable answers/scores' as suggested by Altman and Bland (1983) . The hypothesis of zero bias was examined by a signed-rank test (Snedecor, 1989) . The overlapping (ovl) coefficient (range 0-1) was also used to assess the practical meaning of differences between the SHED and the SHE distributions (Bradley, 1985; Inman and Bradley, 1989) and to complement comparability evaluation. Comparability of scales was tested both overall and separately by centre. The Spearman correlation coefficient between SHED and SHE scores was used to test the construct validity of SHE.
The TTO questions gave an ordinal categorical response format. We expected that patients with lower (worse) values on the SHE scale would be more prepared to give up time in their current state of health in exchange for perfect health. They would hence be willing to trade shorter times in perfect health for the 12 months in their current state of health. A Wilcoxon-type test for trend proposed by Cuzick (1985) was used to provide evidence for the validity of the SHE scale against TTO. We also tested for a linear trend in all HRQL LASA scales across TTO answers.
The impact of biomedical and sociodemographic factors on SHE was analysed with ANOVA.
A power transformation of LASA score to 1T0 utility scores has been proposed for a 'death' to 'perfect health' scale (Torrance, 1976) and for 'worst imaginable health' to' best imaginable health' scale (van Busschbach, 1994) . We therefore estimated the parameter alpha of the model SHE = 1 -(1 -TTO)alpha from a straight-line regression analysis through the origin of log (1 -SHE) on Subjective health estimations in breast cancer patients 987 an independent variable (TTO-SHE). The aims were to compare our results with the published data and to verify how to predict TTO from SHE.
Statistical analyses were carried out with STATA.
RESULTS

Patient accrual
Between October 1992 and January 1993, a total of 83 potentially eligible patients were reported in the German-speaking area (two centres). Of these, 24 patients (29%) refused, the main reasons for refusal being low performance status and reluctance to speak about illness-related topics in an interview, seven (8%) could not be interviewed for logistical reasons and four (5%) 
Feasibility and acceptability
All the questions were generally well accepted. Answers concerning the reaction to the investigation were available from 45 (94%) of the 48 patients interviewed in the German-speaking area (two patients declined this evaluation and one patient responded only in part). The answers of 5 out of 45 patients could not be rated into the predefined categories. Thirty patients (63%) described the interview in general as being no problem or interesting. For 17 patients, the questions were difficult, and eight patients judged them as causing distress (some of these had also described the questionnaire overall as interesting).
Most patients (n = 34, 71%) classified the LASA questions on physical well-being, appetite, mood and coping as easiest, while either SHE/SHED or the TTO questions were judged easiest by ten patients (21%) and, for one patient (2%), no questions could be classified as easiest. For 15 patients (31%), the TTO question was the most difficult one. Only seven patients (15%) found SHE or SHED most difficult, but the majority described the SHED as being more difficult than the SHE. Two patients (4%) did not classify any question as most difficult.
Subjective responses to SHE and SHED
We asked the same 45 responding patients about the thoughts that crossed their mind in placing the marks on the SHED and SHE scales. Three types of responses were obtained. Twenty-seven patients thought about their present state of health in a realistic way when placing their marks on the scale, and that they felt neither dead nor completely healthy. The means in this group were 60.5 and 67.4 for SHE and SHED respectively. Wishful thinking was evident in eight patients who would have liked to place the mark at the 'perfect health' end of the scale because they wished so much to be healthy. This influenced their placement of the mark equally as strongly as their knowledge that they were not in perfect health. Their mean scores on the health-state-estimation questions were higher than in the 'realistic' group (70.8 for SHE and 70.9 for SHED). Seven patients specifically stated that they did not like the word 'death' appearing on the anchor point of one of the LASA scales, did not want to think about anything to do with death and therefore had placed their mark as far away from the 'death' end of the scale as possible. This was reflected in substantially higher means for SHED (77.7) compared with SHE (63.9). The remaining three patients gave other answers, such as general statements about illness or comments unrelated to the questions.
Comparison of SHE with SHED
To test construct validity, we first investigated the comparative qualities of SHE and SHED in patients from the German-speaking area. The two scales showed a strong correlation (Spearman r = 0.80, P < 0.0001; Figure IA ). Figure lB . The lack of agreement between the two scales was apparently worse in patients reporting higher SHED scores. However, the betweenmethod difference (SHED -SHE) was not significantly related to the absolute score [(SHED + SHE)/2, r = 0.25]. The mean of the individual differences (SHED -SHE, 'relative bias') was 4.7 (95% confidence interval -0.1-9.3) and its standard deviation (estimate of 'error') was 16.1. The null hypothesis of a zero bias was not rejected (signed-rank test P = 0.09). In this context, a difference of less than five points in scales ranging from 0 to 100 would not be considered clinically important. The scales showed high overlapping coefficients, > 0.99 if the variances were assumed equal and 0.89 if they were allowed to differ, indicating substantial overlap of the two distributions.
Except for generally lower scores at one centre, which could be attributed to more patients with poor performance status, the results were similar across both centres investigated.
Comparison of SHE with TTO
Given the strong correlation of the two scales, the minimal and presumably clinically not relevant differences observed, and the better acceptability of the SHE scale, we decided to drop the SHED. For further validation and clinical use, we compared the SHE scale with TTO scenarios. In the following analyses, patients' data from all language centres (German, French and Italian speaking) were included. The comparison of SHE scores from the German and other centres showed that the scoring behaviour in all three language areas was sufficiently similar to justify merging the data. Table 2 shows mean SHE scores for each possible value of TTO and for grouped values of TTO (12 vs 9 or 11 vs 3 or 6 vs 0 or 1 month) corresponding to 'perfect, good, fair and poor' utilities. The test for trend was highly significant in both analyses (P < 0.001).
Influence of patient characteristics and treatment on SHE SHE scores were significantly different in patient groups according to time since diagnosis (see Table 1 ). The mean SHE scores (s.d.) were 61.7 (20.0) for 11 patients with diagnosis in the previous 2 years, 52.3 (28.8) with diagnosis between 2 and 5 years (36 patients), 54 (23.5) with diagnosis between 5 and 10 years (26 patients) and 78.9 (18.5) with diagnosis more than 10 years before interview ( 1 patients) (ANOVA P = 0.02). Age reached borderline significance with older patients (> 56 years, 38 patients), showing lower mean values (53 vs 61) on the SHE scale (ANOVA P = 0.04). Treatment type also affected SHE scores. Mean score for 36 patients receiving hormonal or no treatment was 62.8 (23.4), while it was 65.1 (22.1) for 15 patients receiving mild chemotherapy and 48.3 (28.5) for 33 patients receiving intensive chemotherapy (ANOVA P = 0.03).
Comparison of SHE with HRQL LASA scores
In the total sample, in order to assess discriminant validity of SHE (i.e. whether this scale assesses something substantially different than the other LASA scales), correlations and tests for trend were also performed for all HRQL scales (physical well-being, appetite, mood and coping) with TTO to compare the strength of their associations. There was no significant association/trend between the TTO and the LASA scales for mood and coping. Although the association between SHE and TTO was stronger (linear-trend test P < 0.001), the scales for physical well-being and appetite also showed a significant linear-trend association with TTO (P = 0.03 and 0.01 respectively). Patients seemed to be more willing to trade time in current health when their physical condition was less good. The correlation between physical well-being or appetite and SHE was moderate (r = 0.51 and 0.42 respectively).
Transformation of SHE-TTO
In a final step, we explored a power transformation of SHE scores to TTO utility scores (SHE-TTO) and vice versa (TTO-SHE). In the 48 German-speaking patients, and in contrast to others (Stiggelbout et al, 1996) , we obtained a satisfactory fit at the individual patient level (r2 = 0.65) for the SHE-TTO. Our (Llewellyn et al, 1982; Gerard et al, 1993; Ashby et al, 1994 (Mummendey, 1987, pp. 104-109) . Criterion validity is supported if the individual patient's answer on the scale corresponds with relevant outside criteria, assessed independently of the values given on the health estimation scale (Mummendey, 1987, pp. 81-83) . We have shown criterion validity by demonstrating plausibly different mean values of SHE for groups of patients with different treatments and age. Different times since diagnosis as an indication of aggressiveness of disease also had a substantial impact on SHE scores. However, the trend of this association was not linear and needs further study. Our results showed that the answers that patients gave on both scales (SHE and SHED) were comparable.
To determine whether SHE measures something different to the other LASA scales used in the HRQL questionnaire, we compared all LASA scales with TTO answers. As the relationship between SHE and TTO was stronger than between the other LASA scales and TTO, this would give an indication of discriminant validity of SHE (Mummendey, 1987, pp. 84-85; Streaner and Norman, 1995) .
The more time in their current health state that patients were prepared to trade for a lesser amount of time in perfect health, the lower were their health-state-estimation values on the SHE scale. This linear trend was highly significant. Our estimate of alpha for the SHE-TTO transformation (0.42, s.d. 0.05) was similar to that obtained by van Busschbach (1994) , who also used an anchor of 'worst imaginable health' rather than 'death', but lower than the value proposed by Torrance (1986) and by Stiggelbout et al (1996) ; these two studies used a scale anchored by death and perfect health. Thus, the appropriate value of alpha for transformation may depend on the type of scale used, but both types of scale seem to allow transformation from LASA to TTO scores, so that patient self-assessment scores can be transformed for use in decision models. Additional research is needed to explain the observed power relationship (including the validity of the transformation). Different disease settings, being on treatment or not and other factors could be influencing this power function. Before using such a transformation, sensitivity analyses should be carried out and careful evaluation of small changes in the coefficient on the TTO should be performed.
While SHE had the most consistent relationship with FTO, a significant association was also found between the physical aspects of HRQL and the answers to the TTO questions. Patients seemed to be more prepared to trade some time in their current state of health when their physical condition was less good.
An open issue with regard to SHE is its subjective meaning to the individual patient filling in the scale. This issue is relevant generally in HRQL assessment and has been addressed by several authors (Schag et al, 1984; Slevin et al, 1988; Jenkins, 1992) . We attempted to shed some light on this by asking patients about their thoughts when completing the scale. Their answers indicated some heterogeneity, as suspected by Jancik and Yates (1986) . However, a large proportion of our patients scored the scale on the basis of thoughts about their current health.
Denial is a common coping style among cancer patients; this may affect SHE scores, as could be seen from the much higher means on SHE for the unrealistically optimistic patients and the divergence between SHE and SHED for patients who reacted unfavourably to the concept of death on the SHED scale. This may also apply to other self-assessment HRQL scales. Our patients with metastatic breast cancer assessed their health state as relatively high. More than half of the patients would have traded no or only a very short time of their current condition for British Journal of Cancer (1998) 77(6), [985] [986] [987] [988] [989] [990] [991] 0 Cancer Research Campaign 1998 time in perfect health. This strong weighting of survival time per se is also reflected by the tendency to readily accept very discomforting health states with small gains in survival time observed in other studies with breast cancer patients (Coates and Simes, 1992; McQuellon et al, 1995) .
We conclude from our study of the SHE scale in a limited sample of patients with metastatic breast cancer from three cultures that this simple scale is a feasible and valid method to assess the value patients attribute to their current state of health, especially for large-scale cancer clinical trials including patients from various countries and cultures. We have provided strong evidence that it can be transformed to give an adapted concept of utility, which can be incorporated as an approximation into quality-adjusted survival analysis, such as QALYs (Miyamoto, 1985; Carr-Hill, 1989; Mehrez, 1989) or Q-TWiST (Gelber and Goldhirsch, 1986; Goldhirsch et al, 1989) . As SHE is patient derived, it is arguably preferable to arbitrary utility values assigned by investigators. We are currently assessing subjective health estimations by SHE in the large-scale international adjuvant breast cancer trials of the International Breast Cancer Study Group, in parallel with our conventional HRQL indicators. These studies will give us the opportunity to further investigate this scale, with special emphasis on cross-cultural factors, sensitivity to changes over time from diagnosis and the impact of different treatments and of disease relapse.
